FGFR2 and endometrial carcinoma: For example FGFR1 amplification is recurrently seen in less than 20% of squamous non-small-cell lung carcinoma (NSCLC) and breast cancer, while somatic activating mutations are more common in FGFR2 and FGFR3, with FGFR2 mutations involving 10–12% of endometrial carcinomas and approximately 4% of NSCLCs and gastric cancers, and FGFR3 being highly recurrent in urothelial carcinomas [24,46,47].